Published in Surgery on December 01, 1998
Adrenal cortical carcinoma. World J Surg (2001) 1.74
Surgical management of adrenal metastases. Langenbecks Arch Surg (2011) 1.06
Bilateral primary adrenal lymphoma presenting with adrenal insufficiency. Case Rep Endocrinol (2012) 0.95
Imaging of the adrenal gland lesions. Radiol Bras (2015) 0.80
Prognostic factors for recurrence-free and overall survival after adrenalectomy for metastatic carcinoma: a retrospective cohort pilot study. BMC Urol (2014) 0.80
Bilateral adrenal incidentalomas: a case report and review of diagnostic challenges. Case Rep Endocrinol (2013) 0.78
The indeterminate adrenal mass. Langenbecks Arch Surg (2011) 0.76
Incidental Adrenal Nodules and Masses: The Imaging Approach. Int J Endocrinol (2015) 0.75
Adrenal imaging (Part 2): Medullary and secondary adrenal lesions. Indian J Endocrinol Metab (2015) 0.75
Correlation between radiologic and pathologic dimensions of adrenal masses. World J Surg (2004) 0.75
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1979) 6.10
Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science (1995) 4.25
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ (2000) 3.95
Is dialysis hypotension caused by an abnormality of venous tone? Br Med J (Clin Res Ed) (1988) 3.48
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab (2003) 3.24
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res (2001) 2.27
Regulation of alternative polyadenylation by U1 snRNPs and SRp20. Mol Cell Biol (1998) 2.26
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol (2001) 2.24
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med (1984) 2.10
An intron enhancer recognized by splicing factors activates polyadenylation. Genes Dev (1996) 2.08
Polypyrimidine tract-binding protein positively regulates inclusion of an alternative 3'-terminal exon. Mol Cell Biol (1999) 2.05
Increased efficiency of calcium absorption during short periods of inadequate calcium intake in girls. Am J Clin Nutr (1996) 2.04
Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer (1990) 2.01
Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg (1997) 2.00
Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc (1979) 1.94
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
Changes in leucocyte migration after renal transplantation. Br Med J (1969) 1.91
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol (1995) 1.89
Blood loss using the modified two-layer Kiil dialyser. Br Med J (1967) 1.89
Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ (2001) 1.89
Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs. chloroquine syrup. Trop Med Int Health (2001) 1.88
Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg (2001) 1.87
The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab (1992) 1.86
Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood (1993) 1.80
Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol (1998) 1.78
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg (1996) 1.77
Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging (1996) 1.76
Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med (1994) 1.75
Adrenal cortical carcinoma. World J Surg (2001) 1.74
What are the priorities for prevention and control of non-communicable diseases and injuries in sub-Saharan Africa and South East Asia? BMJ (2012) 1.72
Gastrointestinal complications after renal transplantation. Lancet (1971) 1.71
Pancreatic leak after left pancreatectomy is reduced following main pancreatic duct ligation. Br J Surg (2003) 1.71
The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas (1996) 1.68
Liver transplantation in man. II. A report of two orthotopic liver transplants in adult recipients. Br Med J (1968) 1.68
An intron enhancer containing a 5' splice site sequence in the human calcitonin/calcitonin gene-related peptide gene. Mol Cell Biol (1995) 1.67
Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy. Ann Surg Oncol (2000) 1.65
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res (1999) 1.60
Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery (2001) 1.60
Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab (1997) 1.59
Laparoscopy in the staging of pancreatic cancer. Br J Surg (2001) 1.59
Pharmacologic intervention can reestablish baseline hemodynamic parameters during laparoscopy. Surgery (1994) 1.59
A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol (2000) 1.58
Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol (1976) 1.57
Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ (2001) 1.55
Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology (1996) 1.54
Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) (1984) 1.51
Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A (1992) 1.49
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res (2001) 1.46
Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 1.45
Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg (1997) 1.44
The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res (1997) 1.43
Plasma lipids following renal transplantation. Transplantation (1973) 1.42
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene (2001) 1.41
Adenosine receptors mediating cardiac depression. Life Sci (1982) 1.41
The safety and cost-effectiveness of low osmolar contrast media. Can economic analysis determine the real worth of a new technology? Med J Aust (1991) 1.40
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. Int J Radiat Oncol Biol Phys (1995) 1.39
Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol (1986) 1.37
Adrenal cortical carcinoma. Cancer (1989) 1.37
Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg (1998) 1.35
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg (1996) 1.35
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res (1997) 1.34
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33
Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid (1998) 1.33
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
Identification of exon sequences and an exon binding protein involved in alternative RNA splicing of calcitonin/CGRP. Nucleic Acids Res (1992) 1.31
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol (1998) 1.29
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 1.27
Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain (2001) 1.27
Kidney graft survival and matching for HL-A and ABO antigens. Nature (1973) 1.27
Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res (1997) 1.27
Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol (1988) 1.25
The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab (2012) 1.25
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg (1994) 1.25
Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg (2000) 1.24